The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia

Not Applicable

• Conditions: Alopecia

• Registration Number: NCT00197379
• Lead Sponsor: Hamamatsu University

Brief Summary

The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.

Detailed Description

The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.

Study Timeline

• Status Verified: 2005-04
• Study Start: 2005-05
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-20
• Study Completion: 2007-01
• Last Update Submitted: 2010-07-28
• Last Update Posted: 2010-07-29

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Androgenetic alopecia

Read More

Exclusion Criteria

• Cicatricial alopecia
• Allergy to roxitromycin
• Children (19years old or younger)
• Pregnant female

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Trial Locations

Locations (1)

Department of Dermatology, Hamamatsu University School of Medicine; 🇯🇵 Hamamatsu, Japan